A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen

Summary

To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count between 100 and 300 cells/mm3.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications